Abilify Maintena 400mg Dosing Window After 30 Days
If you are at exactly 30 days (4 weeks and 2 days) from the last Abilify Maintena 400mg injection, you can administer the next dose immediately, as the recommended dosing interval is monthly with no sooner than 26 days between injections. 1
Standard Dosing Schedule
The FDA-approved dosing for Abilify Maintena 400mg is:
- Monthly administration (no sooner than 26 days after the previous injection) 1
- This creates a dosing window of 26-30+ days for routine administration
At 30 days post-injection, you are well within the acceptable timeframe and should proceed with the scheduled dose.
Missed Dose Management Algorithm
The specific timing matters significantly for determining your approach:
If This is the 2nd or 3rd Dose:
- 4-5 weeks since last injection: Give the injection immediately 1
- >5 weeks since last injection: Must restart with either 1-day or 14-day initiation protocol 1
If This is the 4th or Subsequent Dose:
- 4-6 weeks since last injection: Give the injection immediately 1
- >6 weeks since last injection: Must restart with either 1-day or 14-day initiation protocol 1
Practical Dosing Window
Recent clinical guidance suggests Abilify Maintena allows a ±7 day window around the scheduled monthly date 2. This means:
- Earliest: Day 26 (4 weeks minus 2 days)
- Target: Day 28-30 (monthly)
- Latest without intervention: Day 35 (5 weeks for doses 2-3, or 6 weeks for dose 4+)
At 30 days, you are in the optimal dosing window and should administer the injection without delay.
Critical Caveats
- Do not wait beyond the appropriate window (5 or 6 weeks depending on dose number), as this necessitates complete reinitiation with oral overlap 1
- If the injection is anticipated to be ≥14 days late, consider oral bridging with 300mg aripiprazole weekly until the injection can be administered 3 (though this guidance is from lenacapavir, similar principles apply)
- The extended dosing windows (up to 6 weeks for established patients) exist because aripiprazole has a long half-life, but therapeutic levels decline over time 4